Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | CCR5 | P51681 | 2/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22717212 | 0.84 | OPRD1 (0.37) | SLC6A2SLC6A4SLC6A3RAB9A | |
| SCHEMBL25474509 | 0.83 | SLC6A2 (0.37) | ACP3SLC6A2SLC6A4SLC6A3CCR5 | |
| SCHEMBL25474388 | 0.80 | SLC6A2 (0.43) | ACP3SLC6A2SLC6A4SLC6A3HSD17B2 | |
| SCHEMBL25474391 | 0.80 | SLC6A2 (0.43) | ACP3SLC6A2SLC6A4SLC6A3HSD17B2 | |
| SCHEMBL25474392 | 0.76 | HSD17B2 (0.37) | ACP3SLC6A2SLC6A4SLC6A3HSD17B2 | |
| SCHEMBL25474461 | 0.76 | HSD17B2 (0.37) | ACP3SLC6A2SLC6A4SLC6A3HSD17B2 | |
| SCHEMBL18501542 | 0.74 | FFAR1 (0.43) | NPC1RAB9AKMT2A | |
| SCHEMBL18501544 | 0.74 | FFAR1 (0.43) | NPC1RAB9AKMT2A | |
| SCHEMBL22724744 | 0.74 | KMT2A (0.50) | KMT2A | |
| SCHEMBL29454658 | 0.74 | KMT2A (0.50) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151037-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151037-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | ACP3 3443/4885SLC6A2 1148/4885SLC6A4 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.